리서치사:Market Glass, Inc. (Formerly Global Industry Analysts, Inc.)
발행일:2025년 08월
페이지 정보:영문 188 Pages
라이선스 & 가격 (부가세 별도)
한글목차
위체류 약물전달 시스템 아웃소싱 세계 시장은 2030년까지 20억 달러에 달할 전망
2024년에 15억 달러로 추정되는 위체류 약물전달 시스템 아웃소싱 세계 시장은 2024년부터 2030년까지 CAGR 5.2%로 성장하여 2030년에는 20억 달러에 달할 것으로 예측됩니다. 이 보고서에서 분석한 부문 중 하나인 정제 제형은 CAGR 3.8%를 기록하며 분석 기간 종료시에는 6억 1,700만 달러에 달할 것으로 예측됩니다. 액체 제형 부문의 성장률은 분석 기간 동안 CAGR 6.9%로 추정됩니다.
미국 시장은 4억 250만 달러로 추정, 중국은 CAGR 8.0%로 성장할 것으로 예측
미국의 위체류 약물전달 시스템 아웃소싱 시장은 2024년에 4억 250만 달러로 추정됩니다. 세계 2위 경제 대국인 중국은 2024년부터 2030년까지 CAGR 8.0%로 성장하여 2030년에는 3억 9,420만 달러의 시장 규모에 달할 것으로 예측됩니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있고, 분석 기간 동안 CAGR은 각각 2.6%와 5.1%로 예측됩니다. 유럽에서는 독일이 CAGR 3.3%로 성장할 것으로 예측됩니다.
세계의 위체류 약물전달 시스템 아웃소싱 시장 - 주요 동향과 촉진요인 정리
흡수 창이 좁거나 상부 소화관(GI)에서의 용해도가 제한적인 약물의 생체 이용률과 치료 효과를 개선하고자 하는 제약회사들의 요구에 따라, 위체류 약물전달 시스템(GRDDS)의 아웃소싱이 큰 주목을 받고 있습니다. 부유 시스템, 생체접착 시스템, 팽창 및 팽창 시스템, 고밀도 시스템 등 GRDDS 기술은 고도로 전문화되어 있으며, 제형화에 대한 광범위한 전문 지식과 고도의 인프라를 필요로 합니다. 따라서 많은 의약품 개발 기업들은 이러한 복잡한 제제를 효율적으로 시장에 출시하기 위해 기술력과 규제적 노하우를 가진 개발 및 제조 수탁기관(CDMO)과 제휴하고 있습니다.
GRDDS 아웃소싱 시장에 영향을 미치는 주요 동향으로는 서방형 경구용 제제에 대한 수요 증가, 환자 중심의 약물전달에 대한 관심 증가, 경쟁 환경 속에서 제품 차별화의 필요성 등이 있습니다. GRDDS의 채택은 약물 체류시간의 연장이 치료 효과를 높이는 만성 위장병, 심혈관질환, 제2형 당뇨병 치료제에 특히 가치가 있습니다. 대형 제약사들이 핵심 연구개발에 집중하기 위해 내부 업무를 간소화하는 가운데, GRDDS의 제제화, 스케일업, 제조와 같은 비핵심 업무의 아웃소싱은 전략적으로 필수적인 요소로 자리 잡았습니다. 또한, 약물 방출 프로파일의 일관성에 대한 규제 당국의 기대와 라이프사이클 관리의 중요성이 증가함에 따라 이 분야의 전문 파트너의 필요성이 증가하고 있습니다.
GRDDS가 기술적으로 요구되고, 아웃소싱의 매력이 있는 이유는 무엇인가?
위체류 약물전달 시스템은 본질적으로 복잡하며, 위 내 약물 방출 속도론, 부력, 점착성, 팽창을 정확하게 제어해야 하는 고도의 기술을 수반합니다. 이러한 요구사항은 제형 설계, 부형제 선택, 실시간 in vitro/in vivo 상관관계 시험 등에 큰 수요를 가져옵니다. 중소형 제약사의 경우, 특히 초기 단계의 개발에서는 이러한 시스템을 자체적으로 개발할 수 있는 사내 인프라가 부족한 경우가 많습니다. 아웃소싱을 통해 고급 분석 툴, GRDDS에 특화된 부형제 라이브러리, 파일럿 규모의 생산 설비를 자본 부담 없이 이용할 수 있습니다.
또 다른 큰 요인은 고분자 과학에 대한 관심이 높아지면서 위내 체류성 및 약물 흡수성을 개선하기 위해 새로운 생체접착성 고분자 및 하이드로겔이 개발되고 있다는 점입니다. 재료과학 및 방출 제어 플랫폼에 대한 전문성을 갖춘 CDMO는 이제 GRDDS 지원 의약품의 시장 출시 시간을 단축하는 데 있어 중요한 협력자가 되었습니다. 다른 장점으로는 장에서 분해되는 경우가 많고 상부 소화관 흡수의 이점을 가진 경구용 생물학적 제제 및 펩타이드에 대한 수요가 증가함에 따라 제제 제조업체는 GRDDS 경로를 추구하고 있습니다. 많은 제약회사들이 이러한 틈새 역량을 사내에서 활용할 수 있는 경우는 드물기 때문에 아웃소싱 파트너는 이러한 새로운 제형 문제를 해결하는 데 있어 중요한 원동력이 될 수 있습니다.
수요를 형성하고 있는 치료 분야와 최종 용도 동향은?
GRDDS의 치료 용도는 위장 건강이라는 기존의 중점 분야를 넘어 확장되고 있습니다. 소화성궤양, 헬리코박터 파일로리균 제균, 위식도 역류질환(GERD)이 여전히 주요 용도인 반면, 위 부위별 약물전달이 필요한 대사성 질환, 파킨슨병, 감염성 질환 관리에 대한 GRDDS의 용도가 크게 증가하고 있습니다. pH에 의존하는 용해도와 장액 내 안정성이 낮은 약물은 특히 GRDDS에 적합하며, 이 접근법은 재제형 전략과 기존 분자의 수명주기 연장을 위한 매력적인 접근법입니다.
아웃소싱에 대한 수요는 고령화 사회에 대응하고 환자의 순응도를 높이려는 제약사들에 의해 주도되고 있습니다. GRDDS 기술은 투여 횟수를 줄이고 약동학적 프로파일을 개선하여 만성 치료에 필수적인 투여 횟수를 줄일 수 있습니다. 소아 및 노인을 위한 약물전달에서, 부유성 및 점착성 GRDDS는 약물 방출 및 체류 시간 제어를 개선하고 삼킴 및 용량 균일성에 대한 우려를 해결합니다. 사용하기 쉬운 경구용 제형과 이러한 특정 집단에 대한 규제 문서화 지원에 대한 강력한 배경을 가진 주요 기업이 개발 프로젝트를 주도할 수 있도록 적극적으로 요구되고 있습니다.
세계 GRDDS 아웃소싱의 성장 원동력은?
위체류 약물전달 시스템 아웃소싱 시장의 성장은 상부 소화관에 표적 전달이 필요한 약물 분자의 복잡성 증가, 만성 위 질환 및 대사성 질환의 유병률 증가, 생체이용률 개선에 효과적인 약물의 파이프라인 증가 등 여러 요인에 의해 주도되고 있습니다. 라이프사이클 관리와 합성에 대한 관심이 높아지는 등 진화하는 의약품 연구개발 상황은 GRDDS 기술을 위한 비옥한 토양이 되고 있습니다. 아웃소싱을 통해 기업은 CDMO가 제공하는 전문 지식 기반, 자체 배송 플랫폼, 신속한 스케일업 프로세스를 활용할 수 있습니다.
스마트 폴리머, 부유제제용 가스 발생 시스템, 위내 체류성 정제의 첨단 3D 프린팅 등의 기술 혁신은 외주 개발 파트너의 역량을 한층 더 높여주고 있습니다. 또한, GRDDS 대응 제품에 대한 규제 명확화와 QbD(Quality-by-Design)의 중요성이 강조되면서 전문 아웃소싱 업체와의 조기 협업을 촉진하고 있습니다. 인도와 동유럽과 같은 신흥 시장에서의 CDMO 서비스 확대는 과학적 전문성 증가로 인한 비용 우위를 보완하여 아웃소싱 트렌드에 박차를 가하고 있습니다. 제약기업들이 제품 개발에서 민첩성, 혁신성, 신속성을 추구하는 가운데, GRDDS 아웃소싱은 의약품 개발 가치사슬 전반에서 전략적 핵심 분야로 자리매김할 것입니다.
부문
제형(정제 제형, 액제 제형, 마이크로스피어 제형, 캡슐 제형, 기타 제형)
조사 대상 기업 사례
Adare Pharma Solutions
Aenova Group
Almac Group
Aptar Pharma
Ashland Global Holdings Inc.
Catalent, Inc.
Colorcon, Inc.
Convatec Group
CordenPharma International
Evonik Industries AG
Evotec SE
Halozyme Therapeutics
Lonza Group AG
Patheon(Thermo Fisher Scientific)
Pharmaron Beijing Co., Ltd.
Quotient Sciences
Recipharm AB
Rubicon Research Pvt. Ltd.
Siegfried Holding AG
Vectura Group Ltd.
AI 통합
우리는 검증된 전문가 컨텐츠와 AI 툴을 통해 시장 정보와 경쟁 정보를 혁신하고 있습니다.
Global Industry Analysts는 LLM 및 업계 고유의 SLM을 조회하는 일반적인 규범을 따르는 대신 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양의 기업, 제품/서비스, 시장 데이터 등 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.
관세 영향 계수
Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측하고 있습니다. 이러한 복잡하고 다면적인 시장 역학은 매출원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예상됩니다.
목차
제1장 조사 방법
제2장 주요 요약
시장 개요
주요 기업
시장 동향과 촉진요인
세계 시장 전망
제3장 시장 분석
미국
캐나다
일본
중국
유럽
프랑스
독일
이탈리아
영국
스페인
러시아
기타 유럽
아시아태평양
호주
인도
한국
기타 아시아태평양
라틴아메리카
아르헨티나
브라질
멕시코
기타 라틴아메리카
중동
이란
이스라엘
사우디아라비아
아랍에미리트
기타 중동
아프리카
제4장 경쟁
KSM
영문 목차
영문목차
Global Gastroretentive Drug Delivery Systems Outsourcing Market to Reach US$2.0 Billion by 2030
The global market for Gastroretentive Drug Delivery Systems Outsourcing estimated at US$1.5 Billion in the year 2024, is expected to reach US$2.0 Billion by 2030, growing at a CAGR of 5.2% over the analysis period 2024-2030. Tablets Dosage Form, one of the segments analyzed in the report, is expected to record a 3.8% CAGR and reach US$617.0 Million by the end of the analysis period. Growth in the Liquid Dosage Form segment is estimated at 6.9% CAGR over the analysis period.
The U.S. Market is Estimated at US$402.5 Million While China is Forecast to Grow at 8.0% CAGR
The Gastroretentive Drug Delivery Systems Outsourcing market in the U.S. is estimated at US$402.5 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$394.2 Million by the year 2030 trailing a CAGR of 8.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.6% and 5.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.3% CAGR.
Global Gastroretentive Drug Delivery Systems Outsourcing Market - Key Trends & Drivers Summarized
The outsourcing of gastroretentive drug delivery systems (GRDDS) is gaining significant traction as pharmaceutical companies seek to improve bioavailability and therapeutic efficacy of drugs with narrow absorption windows or limited solubility in the upper gastrointestinal (GI) tract. GRDDS technologies such as floating systems, bioadhesive systems, swelling and expanding systems, and high-density systems are highly specialized and require extensive formulation expertise and advanced infrastructure. As a result, many drug developers are partnering with contract development and manufacturing organizations (CDMOs) that possess the technical capabilities and regulatory know-how to bring these complex formulations to market efficiently.
Key trends influencing the GRDDS outsourcing market include rising demand for extended-release oral formulations, increasing focus on patient-centric drug delivery, and the need to differentiate products in a competitive therapeutic landscape. The adoption of GRDDS is particularly valuable for drugs treating chronic gastrointestinal disorders, cardiovascular diseases, and type 2 diabetes, where prolonged drug residence time enhances therapeutic outcomes. As major pharmaceutical firms streamline internal operations to focus on core R&D, outsourcing non-core competencies such as GRDDS formulation, scale-up, and manufacturing has become a strategic imperative. Furthermore, regulatory expectations for consistency in drug release profiles and the growing emphasis on lifecycle management are also driving the need for specialized partners in this space.
What Makes GRDDS So Technically Demanding - And Attractive to Outsource?
Gastroretentive drug delivery systems are inherently complex, involving advanced technologies that must ensure precise control over drug release kinetics, buoyancy, adhesion, or expansion in the stomach. These requirements place significant demands on formulation design, choice of excipients, and real-time in vitro/in vivo correlation testing. Small and mid-sized pharmaceutical companies often lack the in-house infrastructure to develop such systems independently, especially for early-phase development. Outsourcing allows them access to advanced analytical tools, GRDDS-specific excipient libraries, and pilot-scale production facilities without the capital burden.
Another major factor is the growing interest in polymer science, where novel bioadhesive polymers and hydrogels are being developed to improve gastric retention and drug absorption. CDMOs with expertise in material science and controlled-release platforms are now critical collaborators in accelerating time-to-market for GRDDS-enabled drugs. Additionally, the increasing demand for oral biologics and peptides, which often degrade in the intestines and benefit from upper GI absorption, is pushing formulators to seek GRDDS routes. This niche capability is rarely available in-house for many pharmaceutical firms, positioning outsourcing partners as key enablers in addressing these emerging formulation challenges.
Which Therapeutic Areas and End-Use Trends Are Shaping the Demand?
Therapeutic applications of GRDDS are expanding beyond the traditional focus areas of gastrointestinal health. While peptic ulcers, Helicobacter pylori eradication, and gastroesophageal reflux disease (GERD) still dominate usage, there is a marked rise in the application of GRDDS in the management of metabolic disorders, Parkinson’s disease, and infectious diseases requiring site-specific drug delivery in the stomach. Drugs with pH-dependent solubility or poor stability in intestinal fluids are particularly well-suited to GRDDS, making this approach attractive for reformulation strategies and lifecycle extension of existing molecules.
Outsourcing demand is also being driven by pharmaceutical companies aiming to serve aging populations and improve patient adherence. GRDDS technologies enable reduced dosing frequency and enhanced pharmacokinetic profiles, which are essential in chronic therapies. In pediatric and geriatric drug delivery, floating and mucoadhesive GRDDS offer better control over drug release and residence time, addressing swallowability and dose uniformity concerns. Outsourcing companies with a strong background in user-friendly oral dosage forms and regulatory dossier support for these specific populations are being actively sought out to lead development projects.
What’s Fueling the Growth in GRDDS Outsourcing Across the Globe?
The growth in the gastroretentive drug delivery systems outsourcing market is driven by several factors, including the rising complexity of drug molecules requiring targeted delivery in the upper GI tract, the increasing prevalence of chronic gastric and metabolic diseases, and a growing pipeline of drugs that benefit from enhanced bioavailability. The evolving pharmaceutical R&D landscape-with heightened focus on lifecycle management and fixed-dose combinations-has created a fertile ground for GRDDS technologies. Outsourcing enables companies to tap into specialized knowledge bases, proprietary delivery platforms, and faster scale-up processes offered by CDMOs.
Technological innovations such as smart polymers, gas-generating systems for floating formulations, and advanced 3D printing of gastroretentive tablets are further enhancing the capabilities of outsourced development partners. Additionally, regulatory clarity around GRDDS-enabled products and a strong global emphasis on quality-by-design (QbD) are encouraging early engagement with expert outsourcing providers. The expansion of CDMO services in emerging markets like India and Eastern Europe-where cost advantages are complemented by growing scientific expertise-is also fueling the outsourcing trend. As pharmaceutical companies continue to seek agility, innovation, and speed in product development, GRDDS outsourcing is set to remain a strategic focus area across the drug development value chain.
SCOPE OF STUDY:
The report analyzes the Gastroretentive Drug Delivery Systems Outsourcing market in terms of units by the following Segments, and Geographic Regions/Countries:
Segments:
Dosage Form (Tablets Dosage Form, Liquid Dosage Form, Microspheres Dosage Form, Capsule Dosage Form, Other Dosage Forms)
Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.
Select Competitors (Total 41 Featured) -
Adare Pharma Solutions
Aenova Group
Almac Group
Aptar Pharma
Ashland Global Holdings Inc.
Catalent, Inc.
Colorcon, Inc.
Convatec Group
CordenPharma International
Evonik Industries AG
Evotec SE
Halozyme Therapeutics
Lonza Group AG
Patheon (Thermo Fisher Scientific)
Pharmaron Beijing Co., Ltd.
Quotient Sciences
Recipharm AB
Rubicon Research Pvt. Ltd.
Siegfried Holding AG
Vectura Group Ltd.
AI INTEGRATIONS
We're transforming market and competitive intelligence with validated expert content and AI tools.
Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.
TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.
TABLE OF CONTENTS
I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
Tariff Impact on Global Supply Chain Patterns
Gastroretentive Drug Delivery Systems Outsourcing - Global Key Competitors Percentage Market Share in 2025 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Rising Complexity of GRDDS Formulations Spurs Demand for Specialized Outsourcing Partners
Pharma Industry Focus on Core R&D and Cost Reduction Accelerates Outsourcing of Gastroretentive Drug Development
Growing Number of Emerging Biopharma and Virtual Drug Companies Increases Outsourcing Demand for GRDDS
CMOs and CDMOs Expanding Capabilities in Mucoadhesive, Floating, and Swellable GRDDS Boost Outsourcing Opportunities
Need for Specialized Equipment and Regulatory Expertise Drives Contract Manufacturing of GRDDS Technologies
OEM Investments in Dedicated Oral Solid Dosage Lines Enhance Service Offering for Gastroretentive Formulations
Growth in Modified Release and Site-Specific Delivery Markets Creates Outsourcing Opportunities for Niche CDMOs
Increased FDA and EMA Regulatory Stringency Spurs Demand for GRDDS Outsourcing to Compliant Facilities
Collaborative GRDDS Development Models Between Innovators and CMOs Strengthen Speed-to-Market Advantage
Focus on Small Batch, High-Potency Drug Formulation Supports Outsourcing of Clinical-Stage GRDDS Projects
Rising Demand for Analytical and Bioavailability Testing Capabilities Expands Scope of GRDDS Outsourcing
Contract Development Partners Offering 3D Printing and Novel Dosage Platforms Gain Competitive Edge in GRDDS Market
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World Gastroretentive Drug Delivery Systems Outsourcing Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
TABLE 2: World Recent Past, Current & Future Analysis for Gastroretentive Drug Delivery Systems Outsourcing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 3: World Historic Review for Gastroretentive Drug Delivery Systems Outsourcing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 4: World 15-Year Perspective for Gastroretentive Drug Delivery Systems Outsourcing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
TABLE 5: World Recent Past, Current & Future Analysis for Tablets Dosage Form by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 6: World Historic Review for Tablets Dosage Form by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 7: World 15-Year Perspective for Tablets Dosage Form by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 8: World Recent Past, Current & Future Analysis for Liquid Dosage Form by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 9: World Historic Review for Liquid Dosage Form by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 10: World 15-Year Perspective for Liquid Dosage Form by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 11: World Recent Past, Current & Future Analysis for Microspheres Dosage Form by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 12: World Historic Review for Microspheres Dosage Form by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 13: World 15-Year Perspective for Microspheres Dosage Form by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 14: World Recent Past, Current & Future Analysis for Capsule Dosage Form by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 15: World Historic Review for Capsule Dosage Form by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 16: World 15-Year Perspective for Capsule Dosage Form by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 17: World Recent Past, Current & Future Analysis for Other Dosage Forms by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 18: World Historic Review for Other Dosage Forms by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 19: World 15-Year Perspective for Other Dosage Forms by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
III. MARKET ANALYSIS
UNITED STATES
Gastroretentive Drug Delivery Systems Outsourcing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
TABLE 20: USA Recent Past, Current & Future Analysis for Gastroretentive Drug Delivery Systems Outsourcing by Dosage Form - Tablets Dosage Form, Liquid Dosage Form, Microspheres Dosage Form, Capsule Dosage Form and Other Dosage Forms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 21: USA Historic Review for Gastroretentive Drug Delivery Systems Outsourcing by Dosage Form - Tablets Dosage Form, Liquid Dosage Form, Microspheres Dosage Form, Capsule Dosage Form and Other Dosage Forms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 22: USA 15-Year Perspective for Gastroretentive Drug Delivery Systems Outsourcing by Dosage Form - Percentage Breakdown of Value Sales for Tablets Dosage Form, Liquid Dosage Form, Microspheres Dosage Form, Capsule Dosage Form and Other Dosage Forms for the Years 2015, 2025 & 2030
CANADA
TABLE 23: Canada Recent Past, Current & Future Analysis for Gastroretentive Drug Delivery Systems Outsourcing by Dosage Form - Tablets Dosage Form, Liquid Dosage Form, Microspheres Dosage Form, Capsule Dosage Form and Other Dosage Forms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 24: Canada Historic Review for Gastroretentive Drug Delivery Systems Outsourcing by Dosage Form - Tablets Dosage Form, Liquid Dosage Form, Microspheres Dosage Form, Capsule Dosage Form and Other Dosage Forms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 25: Canada 15-Year Perspective for Gastroretentive Drug Delivery Systems Outsourcing by Dosage Form - Percentage Breakdown of Value Sales for Tablets Dosage Form, Liquid Dosage Form, Microspheres Dosage Form, Capsule Dosage Form and Other Dosage Forms for the Years 2015, 2025 & 2030
JAPAN
Gastroretentive Drug Delivery Systems Outsourcing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
TABLE 26: Japan Recent Past, Current & Future Analysis for Gastroretentive Drug Delivery Systems Outsourcing by Dosage Form - Tablets Dosage Form, Liquid Dosage Form, Microspheres Dosage Form, Capsule Dosage Form and Other Dosage Forms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 27: Japan Historic Review for Gastroretentive Drug Delivery Systems Outsourcing by Dosage Form - Tablets Dosage Form, Liquid Dosage Form, Microspheres Dosage Form, Capsule Dosage Form and Other Dosage Forms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 28: Japan 15-Year Perspective for Gastroretentive Drug Delivery Systems Outsourcing by Dosage Form - Percentage Breakdown of Value Sales for Tablets Dosage Form, Liquid Dosage Form, Microspheres Dosage Form, Capsule Dosage Form and Other Dosage Forms for the Years 2015, 2025 & 2030
CHINA
Gastroretentive Drug Delivery Systems Outsourcing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
TABLE 29: China Recent Past, Current & Future Analysis for Gastroretentive Drug Delivery Systems Outsourcing by Dosage Form - Tablets Dosage Form, Liquid Dosage Form, Microspheres Dosage Form, Capsule Dosage Form and Other Dosage Forms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 30: China Historic Review for Gastroretentive Drug Delivery Systems Outsourcing by Dosage Form - Tablets Dosage Form, Liquid Dosage Form, Microspheres Dosage Form, Capsule Dosage Form and Other Dosage Forms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 31: China 15-Year Perspective for Gastroretentive Drug Delivery Systems Outsourcing by Dosage Form - Percentage Breakdown of Value Sales for Tablets Dosage Form, Liquid Dosage Form, Microspheres Dosage Form, Capsule Dosage Form and Other Dosage Forms for the Years 2015, 2025 & 2030
EUROPE
Gastroretentive Drug Delivery Systems Outsourcing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
TABLE 32: Europe Recent Past, Current & Future Analysis for Gastroretentive Drug Delivery Systems Outsourcing by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 33: Europe Historic Review for Gastroretentive Drug Delivery Systems Outsourcing by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 34: Europe 15-Year Perspective for Gastroretentive Drug Delivery Systems Outsourcing by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
TABLE 35: Europe Recent Past, Current & Future Analysis for Gastroretentive Drug Delivery Systems Outsourcing by Dosage Form - Tablets Dosage Form, Liquid Dosage Form, Microspheres Dosage Form, Capsule Dosage Form and Other Dosage Forms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 36: Europe Historic Review for Gastroretentive Drug Delivery Systems Outsourcing by Dosage Form - Tablets Dosage Form, Liquid Dosage Form, Microspheres Dosage Form, Capsule Dosage Form and Other Dosage Forms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 37: Europe 15-Year Perspective for Gastroretentive Drug Delivery Systems Outsourcing by Dosage Form - Percentage Breakdown of Value Sales for Tablets Dosage Form, Liquid Dosage Form, Microspheres Dosage Form, Capsule Dosage Form and Other Dosage Forms for the Years 2015, 2025 & 2030
FRANCE
Gastroretentive Drug Delivery Systems Outsourcing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
TABLE 38: France Recent Past, Current & Future Analysis for Gastroretentive Drug Delivery Systems Outsourcing by Dosage Form - Tablets Dosage Form, Liquid Dosage Form, Microspheres Dosage Form, Capsule Dosage Form and Other Dosage Forms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 39: France Historic Review for Gastroretentive Drug Delivery Systems Outsourcing by Dosage Form - Tablets Dosage Form, Liquid Dosage Form, Microspheres Dosage Form, Capsule Dosage Form and Other Dosage Forms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 40: France 15-Year Perspective for Gastroretentive Drug Delivery Systems Outsourcing by Dosage Form - Percentage Breakdown of Value Sales for Tablets Dosage Form, Liquid Dosage Form, Microspheres Dosage Form, Capsule Dosage Form and Other Dosage Forms for the Years 2015, 2025 & 2030
GERMANY
Gastroretentive Drug Delivery Systems Outsourcing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
TABLE 41: Germany Recent Past, Current & Future Analysis for Gastroretentive Drug Delivery Systems Outsourcing by Dosage Form - Tablets Dosage Form, Liquid Dosage Form, Microspheres Dosage Form, Capsule Dosage Form and Other Dosage Forms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 42: Germany Historic Review for Gastroretentive Drug Delivery Systems Outsourcing by Dosage Form - Tablets Dosage Form, Liquid Dosage Form, Microspheres Dosage Form, Capsule Dosage Form and Other Dosage Forms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 43: Germany 15-Year Perspective for Gastroretentive Drug Delivery Systems Outsourcing by Dosage Form - Percentage Breakdown of Value Sales for Tablets Dosage Form, Liquid Dosage Form, Microspheres Dosage Form, Capsule Dosage Form and Other Dosage Forms for the Years 2015, 2025 & 2030
ITALY
TABLE 44: Italy Recent Past, Current & Future Analysis for Gastroretentive Drug Delivery Systems Outsourcing by Dosage Form - Tablets Dosage Form, Liquid Dosage Form, Microspheres Dosage Form, Capsule Dosage Form and Other Dosage Forms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 45: Italy Historic Review for Gastroretentive Drug Delivery Systems Outsourcing by Dosage Form - Tablets Dosage Form, Liquid Dosage Form, Microspheres Dosage Form, Capsule Dosage Form and Other Dosage Forms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 46: Italy 15-Year Perspective for Gastroretentive Drug Delivery Systems Outsourcing by Dosage Form - Percentage Breakdown of Value Sales for Tablets Dosage Form, Liquid Dosage Form, Microspheres Dosage Form, Capsule Dosage Form and Other Dosage Forms for the Years 2015, 2025 & 2030
UNITED KINGDOM
Gastroretentive Drug Delivery Systems Outsourcing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
TABLE 47: UK Recent Past, Current & Future Analysis for Gastroretentive Drug Delivery Systems Outsourcing by Dosage Form - Tablets Dosage Form, Liquid Dosage Form, Microspheres Dosage Form, Capsule Dosage Form and Other Dosage Forms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 48: UK Historic Review for Gastroretentive Drug Delivery Systems Outsourcing by Dosage Form - Tablets Dosage Form, Liquid Dosage Form, Microspheres Dosage Form, Capsule Dosage Form and Other Dosage Forms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 49: UK 15-Year Perspective for Gastroretentive Drug Delivery Systems Outsourcing by Dosage Form - Percentage Breakdown of Value Sales for Tablets Dosage Form, Liquid Dosage Form, Microspheres Dosage Form, Capsule Dosage Form and Other Dosage Forms for the Years 2015, 2025 & 2030
SPAIN
TABLE 50: Spain Recent Past, Current & Future Analysis for Gastroretentive Drug Delivery Systems Outsourcing by Dosage Form - Tablets Dosage Form, Liquid Dosage Form, Microspheres Dosage Form, Capsule Dosage Form and Other Dosage Forms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 51: Spain Historic Review for Gastroretentive Drug Delivery Systems Outsourcing by Dosage Form - Tablets Dosage Form, Liquid Dosage Form, Microspheres Dosage Form, Capsule Dosage Form and Other Dosage Forms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 52: Spain 15-Year Perspective for Gastroretentive Drug Delivery Systems Outsourcing by Dosage Form - Percentage Breakdown of Value Sales for Tablets Dosage Form, Liquid Dosage Form, Microspheres Dosage Form, Capsule Dosage Form and Other Dosage Forms for the Years 2015, 2025 & 2030
RUSSIA
TABLE 53: Russia Recent Past, Current & Future Analysis for Gastroretentive Drug Delivery Systems Outsourcing by Dosage Form - Tablets Dosage Form, Liquid Dosage Form, Microspheres Dosage Form, Capsule Dosage Form and Other Dosage Forms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 54: Russia Historic Review for Gastroretentive Drug Delivery Systems Outsourcing by Dosage Form - Tablets Dosage Form, Liquid Dosage Form, Microspheres Dosage Form, Capsule Dosage Form and Other Dosage Forms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 55: Russia 15-Year Perspective for Gastroretentive Drug Delivery Systems Outsourcing by Dosage Form - Percentage Breakdown of Value Sales for Tablets Dosage Form, Liquid Dosage Form, Microspheres Dosage Form, Capsule Dosage Form and Other Dosage Forms for the Years 2015, 2025 & 2030
REST OF EUROPE
TABLE 56: Rest of Europe Recent Past, Current & Future Analysis for Gastroretentive Drug Delivery Systems Outsourcing by Dosage Form - Tablets Dosage Form, Liquid Dosage Form, Microspheres Dosage Form, Capsule Dosage Form and Other Dosage Forms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 57: Rest of Europe Historic Review for Gastroretentive Drug Delivery Systems Outsourcing by Dosage Form - Tablets Dosage Form, Liquid Dosage Form, Microspheres Dosage Form, Capsule Dosage Form and Other Dosage Forms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 58: Rest of Europe 15-Year Perspective for Gastroretentive Drug Delivery Systems Outsourcing by Dosage Form - Percentage Breakdown of Value Sales for Tablets Dosage Form, Liquid Dosage Form, Microspheres Dosage Form, Capsule Dosage Form and Other Dosage Forms for the Years 2015, 2025 & 2030
ASIA-PACIFIC
Gastroretentive Drug Delivery Systems Outsourcing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
TABLE 59: Asia-Pacific Recent Past, Current & Future Analysis for Gastroretentive Drug Delivery Systems Outsourcing by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 60: Asia-Pacific Historic Review for Gastroretentive Drug Delivery Systems Outsourcing by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 61: Asia-Pacific 15-Year Perspective for Gastroretentive Drug Delivery Systems Outsourcing by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
TABLE 62: Asia-Pacific Recent Past, Current & Future Analysis for Gastroretentive Drug Delivery Systems Outsourcing by Dosage Form - Tablets Dosage Form, Liquid Dosage Form, Microspheres Dosage Form, Capsule Dosage Form and Other Dosage Forms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 63: Asia-Pacific Historic Review for Gastroretentive Drug Delivery Systems Outsourcing by Dosage Form - Tablets Dosage Form, Liquid Dosage Form, Microspheres Dosage Form, Capsule Dosage Form and Other Dosage Forms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 64: Asia-Pacific 15-Year Perspective for Gastroretentive Drug Delivery Systems Outsourcing by Dosage Form - Percentage Breakdown of Value Sales for Tablets Dosage Form, Liquid Dosage Form, Microspheres Dosage Form, Capsule Dosage Form and Other Dosage Forms for the Years 2015, 2025 & 2030
AUSTRALIA
Gastroretentive Drug Delivery Systems Outsourcing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
TABLE 65: Australia Recent Past, Current & Future Analysis for Gastroretentive Drug Delivery Systems Outsourcing by Dosage Form - Tablets Dosage Form, Liquid Dosage Form, Microspheres Dosage Form, Capsule Dosage Form and Other Dosage Forms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 66: Australia Historic Review for Gastroretentive Drug Delivery Systems Outsourcing by Dosage Form - Tablets Dosage Form, Liquid Dosage Form, Microspheres Dosage Form, Capsule Dosage Form and Other Dosage Forms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 67: Australia 15-Year Perspective for Gastroretentive Drug Delivery Systems Outsourcing by Dosage Form - Percentage Breakdown of Value Sales for Tablets Dosage Form, Liquid Dosage Form, Microspheres Dosage Form, Capsule Dosage Form and Other Dosage Forms for the Years 2015, 2025 & 2030
INDIA
Gastroretentive Drug Delivery Systems Outsourcing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
TABLE 68: India Recent Past, Current & Future Analysis for Gastroretentive Drug Delivery Systems Outsourcing by Dosage Form - Tablets Dosage Form, Liquid Dosage Form, Microspheres Dosage Form, Capsule Dosage Form and Other Dosage Forms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 69: India Historic Review for Gastroretentive Drug Delivery Systems Outsourcing by Dosage Form - Tablets Dosage Form, Liquid Dosage Form, Microspheres Dosage Form, Capsule Dosage Form and Other Dosage Forms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 70: India 15-Year Perspective for Gastroretentive Drug Delivery Systems Outsourcing by Dosage Form - Percentage Breakdown of Value Sales for Tablets Dosage Form, Liquid Dosage Form, Microspheres Dosage Form, Capsule Dosage Form and Other Dosage Forms for the Years 2015, 2025 & 2030
SOUTH KOREA
TABLE 71: South Korea Recent Past, Current & Future Analysis for Gastroretentive Drug Delivery Systems Outsourcing by Dosage Form - Tablets Dosage Form, Liquid Dosage Form, Microspheres Dosage Form, Capsule Dosage Form and Other Dosage Forms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 72: South Korea Historic Review for Gastroretentive Drug Delivery Systems Outsourcing by Dosage Form - Tablets Dosage Form, Liquid Dosage Form, Microspheres Dosage Form, Capsule Dosage Form and Other Dosage Forms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 73: South Korea 15-Year Perspective for Gastroretentive Drug Delivery Systems Outsourcing by Dosage Form - Percentage Breakdown of Value Sales for Tablets Dosage Form, Liquid Dosage Form, Microspheres Dosage Form, Capsule Dosage Form and Other Dosage Forms for the Years 2015, 2025 & 2030
REST OF ASIA-PACIFIC
TABLE 74: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Gastroretentive Drug Delivery Systems Outsourcing by Dosage Form - Tablets Dosage Form, Liquid Dosage Form, Microspheres Dosage Form, Capsule Dosage Form and Other Dosage Forms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 75: Rest of Asia-Pacific Historic Review for Gastroretentive Drug Delivery Systems Outsourcing by Dosage Form - Tablets Dosage Form, Liquid Dosage Form, Microspheres Dosage Form, Capsule Dosage Form and Other Dosage Forms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 76: Rest of Asia-Pacific 15-Year Perspective for Gastroretentive Drug Delivery Systems Outsourcing by Dosage Form - Percentage Breakdown of Value Sales for Tablets Dosage Form, Liquid Dosage Form, Microspheres Dosage Form, Capsule Dosage Form and Other Dosage Forms for the Years 2015, 2025 & 2030
LATIN AMERICA
Gastroretentive Drug Delivery Systems Outsourcing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
TABLE 77: Latin America Recent Past, Current & Future Analysis for Gastroretentive Drug Delivery Systems Outsourcing by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 78: Latin America Historic Review for Gastroretentive Drug Delivery Systems Outsourcing by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 79: Latin America 15-Year Perspective for Gastroretentive Drug Delivery Systems Outsourcing by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
TABLE 80: Latin America Recent Past, Current & Future Analysis for Gastroretentive Drug Delivery Systems Outsourcing by Dosage Form - Tablets Dosage Form, Liquid Dosage Form, Microspheres Dosage Form, Capsule Dosage Form and Other Dosage Forms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 81: Latin America Historic Review for Gastroretentive Drug Delivery Systems Outsourcing by Dosage Form - Tablets Dosage Form, Liquid Dosage Form, Microspheres Dosage Form, Capsule Dosage Form and Other Dosage Forms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 82: Latin America 15-Year Perspective for Gastroretentive Drug Delivery Systems Outsourcing by Dosage Form - Percentage Breakdown of Value Sales for Tablets Dosage Form, Liquid Dosage Form, Microspheres Dosage Form, Capsule Dosage Form and Other Dosage Forms for the Years 2015, 2025 & 2030
ARGENTINA
TABLE 83: Argentina Recent Past, Current & Future Analysis for Gastroretentive Drug Delivery Systems Outsourcing by Dosage Form - Tablets Dosage Form, Liquid Dosage Form, Microspheres Dosage Form, Capsule Dosage Form and Other Dosage Forms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 84: Argentina Historic Review for Gastroretentive Drug Delivery Systems Outsourcing by Dosage Form - Tablets Dosage Form, Liquid Dosage Form, Microspheres Dosage Form, Capsule Dosage Form and Other Dosage Forms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 85: Argentina 15-Year Perspective for Gastroretentive Drug Delivery Systems Outsourcing by Dosage Form - Percentage Breakdown of Value Sales for Tablets Dosage Form, Liquid Dosage Form, Microspheres Dosage Form, Capsule Dosage Form and Other Dosage Forms for the Years 2015, 2025 & 2030
BRAZIL
TABLE 86: Brazil Recent Past, Current & Future Analysis for Gastroretentive Drug Delivery Systems Outsourcing by Dosage Form - Tablets Dosage Form, Liquid Dosage Form, Microspheres Dosage Form, Capsule Dosage Form and Other Dosage Forms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 87: Brazil Historic Review for Gastroretentive Drug Delivery Systems Outsourcing by Dosage Form - Tablets Dosage Form, Liquid Dosage Form, Microspheres Dosage Form, Capsule Dosage Form and Other Dosage Forms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 88: Brazil 15-Year Perspective for Gastroretentive Drug Delivery Systems Outsourcing by Dosage Form - Percentage Breakdown of Value Sales for Tablets Dosage Form, Liquid Dosage Form, Microspheres Dosage Form, Capsule Dosage Form and Other Dosage Forms for the Years 2015, 2025 & 2030
MEXICO
TABLE 89: Mexico Recent Past, Current & Future Analysis for Gastroretentive Drug Delivery Systems Outsourcing by Dosage Form - Tablets Dosage Form, Liquid Dosage Form, Microspheres Dosage Form, Capsule Dosage Form and Other Dosage Forms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 90: Mexico Historic Review for Gastroretentive Drug Delivery Systems Outsourcing by Dosage Form - Tablets Dosage Form, Liquid Dosage Form, Microspheres Dosage Form, Capsule Dosage Form and Other Dosage Forms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 91: Mexico 15-Year Perspective for Gastroretentive Drug Delivery Systems Outsourcing by Dosage Form - Percentage Breakdown of Value Sales for Tablets Dosage Form, Liquid Dosage Form, Microspheres Dosage Form, Capsule Dosage Form and Other Dosage Forms for the Years 2015, 2025 & 2030
REST OF LATIN AMERICA
TABLE 92: Rest of Latin America Recent Past, Current & Future Analysis for Gastroretentive Drug Delivery Systems Outsourcing by Dosage Form - Tablets Dosage Form, Liquid Dosage Form, Microspheres Dosage Form, Capsule Dosage Form and Other Dosage Forms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 93: Rest of Latin America Historic Review for Gastroretentive Drug Delivery Systems Outsourcing by Dosage Form - Tablets Dosage Form, Liquid Dosage Form, Microspheres Dosage Form, Capsule Dosage Form and Other Dosage Forms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 94: Rest of Latin America 15-Year Perspective for Gastroretentive Drug Delivery Systems Outsourcing by Dosage Form - Percentage Breakdown of Value Sales for Tablets Dosage Form, Liquid Dosage Form, Microspheres Dosage Form, Capsule Dosage Form and Other Dosage Forms for the Years 2015, 2025 & 2030
MIDDLE EAST
Gastroretentive Drug Delivery Systems Outsourcing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
TABLE 95: Middle East Recent Past, Current & Future Analysis for Gastroretentive Drug Delivery Systems Outsourcing by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 96: Middle East Historic Review for Gastroretentive Drug Delivery Systems Outsourcing by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 97: Middle East 15-Year Perspective for Gastroretentive Drug Delivery Systems Outsourcing by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
TABLE 98: Middle East Recent Past, Current & Future Analysis for Gastroretentive Drug Delivery Systems Outsourcing by Dosage Form - Tablets Dosage Form, Liquid Dosage Form, Microspheres Dosage Form, Capsule Dosage Form and Other Dosage Forms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 99: Middle East Historic Review for Gastroretentive Drug Delivery Systems Outsourcing by Dosage Form - Tablets Dosage Form, Liquid Dosage Form, Microspheres Dosage Form, Capsule Dosage Form and Other Dosage Forms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 100: Middle East 15-Year Perspective for Gastroretentive Drug Delivery Systems Outsourcing by Dosage Form - Percentage Breakdown of Value Sales for Tablets Dosage Form, Liquid Dosage Form, Microspheres Dosage Form, Capsule Dosage Form and Other Dosage Forms for the Years 2015, 2025 & 2030
IRAN
TABLE 101: Iran Recent Past, Current & Future Analysis for Gastroretentive Drug Delivery Systems Outsourcing by Dosage Form - Tablets Dosage Form, Liquid Dosage Form, Microspheres Dosage Form, Capsule Dosage Form and Other Dosage Forms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 102: Iran Historic Review for Gastroretentive Drug Delivery Systems Outsourcing by Dosage Form - Tablets Dosage Form, Liquid Dosage Form, Microspheres Dosage Form, Capsule Dosage Form and Other Dosage Forms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 103: Iran 15-Year Perspective for Gastroretentive Drug Delivery Systems Outsourcing by Dosage Form - Percentage Breakdown of Value Sales for Tablets Dosage Form, Liquid Dosage Form, Microspheres Dosage Form, Capsule Dosage Form and Other Dosage Forms for the Years 2015, 2025 & 2030
ISRAEL
TABLE 104: Israel Recent Past, Current & Future Analysis for Gastroretentive Drug Delivery Systems Outsourcing by Dosage Form - Tablets Dosage Form, Liquid Dosage Form, Microspheres Dosage Form, Capsule Dosage Form and Other Dosage Forms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 105: Israel Historic Review for Gastroretentive Drug Delivery Systems Outsourcing by Dosage Form - Tablets Dosage Form, Liquid Dosage Form, Microspheres Dosage Form, Capsule Dosage Form and Other Dosage Forms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 106: Israel 15-Year Perspective for Gastroretentive Drug Delivery Systems Outsourcing by Dosage Form - Percentage Breakdown of Value Sales for Tablets Dosage Form, Liquid Dosage Form, Microspheres Dosage Form, Capsule Dosage Form and Other Dosage Forms for the Years 2015, 2025 & 2030
SAUDI ARABIA
TABLE 107: Saudi Arabia Recent Past, Current & Future Analysis for Gastroretentive Drug Delivery Systems Outsourcing by Dosage Form - Tablets Dosage Form, Liquid Dosage Form, Microspheres Dosage Form, Capsule Dosage Form and Other Dosage Forms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 108: Saudi Arabia Historic Review for Gastroretentive Drug Delivery Systems Outsourcing by Dosage Form - Tablets Dosage Form, Liquid Dosage Form, Microspheres Dosage Form, Capsule Dosage Form and Other Dosage Forms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 109: Saudi Arabia 15-Year Perspective for Gastroretentive Drug Delivery Systems Outsourcing by Dosage Form - Percentage Breakdown of Value Sales for Tablets Dosage Form, Liquid Dosage Form, Microspheres Dosage Form, Capsule Dosage Form and Other Dosage Forms for the Years 2015, 2025 & 2030
UNITED ARAB EMIRATES
TABLE 110: UAE Recent Past, Current & Future Analysis for Gastroretentive Drug Delivery Systems Outsourcing by Dosage Form - Tablets Dosage Form, Liquid Dosage Form, Microspheres Dosage Form, Capsule Dosage Form and Other Dosage Forms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 111: UAE Historic Review for Gastroretentive Drug Delivery Systems Outsourcing by Dosage Form - Tablets Dosage Form, Liquid Dosage Form, Microspheres Dosage Form, Capsule Dosage Form and Other Dosage Forms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 112: UAE 15-Year Perspective for Gastroretentive Drug Delivery Systems Outsourcing by Dosage Form - Percentage Breakdown of Value Sales for Tablets Dosage Form, Liquid Dosage Form, Microspheres Dosage Form, Capsule Dosage Form and Other Dosage Forms for the Years 2015, 2025 & 2030
REST OF MIDDLE EAST
TABLE 113: Rest of Middle East Recent Past, Current & Future Analysis for Gastroretentive Drug Delivery Systems Outsourcing by Dosage Form - Tablets Dosage Form, Liquid Dosage Form, Microspheres Dosage Form, Capsule Dosage Form and Other Dosage Forms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 114: Rest of Middle East Historic Review for Gastroretentive Drug Delivery Systems Outsourcing by Dosage Form - Tablets Dosage Form, Liquid Dosage Form, Microspheres Dosage Form, Capsule Dosage Form and Other Dosage Forms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 115: Rest of Middle East 15-Year Perspective for Gastroretentive Drug Delivery Systems Outsourcing by Dosage Form - Percentage Breakdown of Value Sales for Tablets Dosage Form, Liquid Dosage Form, Microspheres Dosage Form, Capsule Dosage Form and Other Dosage Forms for the Years 2015, 2025 & 2030
AFRICA
Gastroretentive Drug Delivery Systems Outsourcing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
TABLE 116: Africa Recent Past, Current & Future Analysis for Gastroretentive Drug Delivery Systems Outsourcing by Dosage Form - Tablets Dosage Form, Liquid Dosage Form, Microspheres Dosage Form, Capsule Dosage Form and Other Dosage Forms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 117: Africa Historic Review for Gastroretentive Drug Delivery Systems Outsourcing by Dosage Form - Tablets Dosage Form, Liquid Dosage Form, Microspheres Dosage Form, Capsule Dosage Form and Other Dosage Forms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 118: Africa 15-Year Perspective for Gastroretentive Drug Delivery Systems Outsourcing by Dosage Form - Percentage Breakdown of Value Sales for Tablets Dosage Form, Liquid Dosage Form, Microspheres Dosage Form, Capsule Dosage Form and Other Dosage Forms for the Years 2015, 2025 & 2030